Dr. Flinn Discusses IPI-145 as Potential Treatment for Hematologic Malignancies

Ian W. Flinn, MD, PhD
Published: Tuesday, Aug 26, 2014

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Flinn says this agent builds on work that has been previously done with delta-specific PI3K inhibitors such as idelalisib. IPI-145 also picks up the gamma isoform, which may help treat other hematologic malignancies such as T cell lympohomas and more aggressive forms of lymphoma.

T cells are important in perpetuating the malignancy in lymphoma and CLL, Flinn says. Targeting the gamma isoform abrogates the protective effect of the microenvironment on the cancer cell.

SELECTED
LANGUAGE
Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

Flinn says this agent builds on work that has been previously done with delta-specific PI3K inhibitors such as idelalisib. IPI-145 also picks up the gamma isoform, which may help treat other hematologic malignancies such as T cell lympohomas and more aggressive forms of lymphoma.

T cells are important in perpetuating the malignancy in lymphoma and CLL, Flinn says. Targeting the gamma isoform abrogates the protective effect of the microenvironment on the cancer cell.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x